Obesity is has become a major problem worldwide. Since 1975, the prevalence of obesity nearly trippled, and nowadays we are facing an obesity epidemic. Obesity is a major risk factor for many diseases such as cardiovascular ones (mainly heart disease and stroke) -being the leading cause of death worldwide, musculoskeletal disorders or type 2 diabetes mellitus (DM).

Rheumatoid arthritis (RA) is the most widespread inflammatory rheumatic disease with about 10% of all rheumatic diseases and a global prevalence of about 1%. Through its features - joint proliferation, articular panic, articular cartilage degradation and bone erosion � RA has a destructive and disabling character and a major socio-economic impact. Osteoporosis is a bone system disease characterized by loss of bone mass and alteration of bone architecture, with consequences on bone fragility correlated with an increased fracture risk. With a major socio-economic impact, the World Health Organization (WHO) has declared osteoporosis as a public health problem, third on cardiovascular and oncological.

Teriparatide (TPT) is the active 1-34 amino acid sequence with osteoanabolic use for severe osteoporosis. Our aim is to analyze the biochemical and clinical profile of patients treated with TPT based on Romanian protocol. The inclusion and exclusion criteria are based on specific country protocol for TPT 20 �g/day, for 2 years, once in life time based on self administration. This is a transversal study including data of a tertiary centre of endocrinology on patients who signed the informed consent. This is a real life study, of observational type (the intervention meaning the TPT recommendation was done by individual decision of each clinician). Normal total and ionic calcium is associated with low 25-hydroxyvitamin D levels and a mean lumbar T-score of -3.1�0.7SD. 50% of patients treated with TPT have digestive conditions, less than 10% are first time users, a high severity profile is based on a median of 4 years regarding prior anti-osteoporotic medication and of 3 previous fragility fractures.

L'indice d'adiposité viscérale (IAV) -marqueur potentiel du risque cardio-métabolique L'importance du risque cardiovasculaire/cardio-métabolique est particulière car le contrôle de ses composantes peut affecter l'athérogenèse et ses conséquences cliniques: la cardiopathie ischémique, la maladie cérébrovasculaire, l'artériopathie périphérique et le diabète sucré (DS). Pour évaluer le risque cardio-métabolique associé à l'obésité viscérale, on a essayé d'identifier un indicateur utile dans la pratique clinique. L'indice d'adiposité viscérale (IAV) pourrait devenir un outil facile à utiliser dans la pratique quotidienne qui met en évidence le risque cardio-métabolique. IAV indique la fonction du tissu adipeux viscéral et sa croissance est indépendamment corrélée aux risques cardiovasculaire et cérébrovasculaire. Le monde médical a essayé d'identifier un moyen facile d'évaluer le risque cardiovasculaire, de sorte que l'indice d'adiposité viscérale, dont la formule inclut un certain nombre de facteurs de risque cardiovasculaires, ait été introduit.

Type 1 diabetes mellitus (T1DM) is a chronic disease which represents a major issue for public health. Type 1 diabetes is occurred most frequently in childhood and adolescence, although in recent years due to the increase in the prevalence of obesity in this category of population has been registered a growing number of cases of type 2 diabetes among children and adolescents (1, 2).